Oncotarget

Research Papers:

Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death

Enyu Rao, Yuwen Zhang, Ganqian Zhu, Jiaqing Hao, Xuan-Mai T. Persson, Nejat K. Egilmez, Jill Suttles and Bing Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:7944-7958. https://doi.org/10.18632/oncotarget.3501

Metrics: PDF 1244 views  |   HTML 1674 views  |   ?  


Abstract

Enyu Rao1, Yuwen Zhang1, Ganqian Zhu1, Jiaqing Hao1, Xuan-Mai T. Persson2, Nejat K. Egilmez3, Jill Suttles3 and Bing Li1

1 The Hormel Institute, University of Minnesota, Austin, MN, USA

2 Center for Clinical and Translational Science Metabolomics Core, Mayo Clinic, Rochester, MN, USA

3 Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA

Correspondence to:

Bing Li, email:

Keywords: AMPK, CD8+ T cells, T cell survival, anti-tumor function

Received: January 27, 2015 Accepted: February 03, 2015 Published: March 09, 2015

Abstract

A number of studies have linked AMPK, a major metabolic sensor coordinating of multiple cellular functions, to tumor development and progression. However, the exact role of AMPK in tumor development is still controversial. Here we report that activation of AMPK promotes survival and anti-tumor function of T cells, in particular CD8+ T cells, resulting in superior tumor suppression in vivo. While AMPK expression is dispensable for T cell development, genetic deletion of AMPK promotes T cell death during in vitro activation and in vivo tumor development. Moreover, we demonstrate that protein phosphatases are the key mediators of AMPK-dependent effects on T cell death, and inhibition of phosphatase activity by okadaic acid successfully restores T cell survival and function. Altogether, our data suggest a novel mechanism by which AMPK regulates protein phosphatase activity in control of survival and function of CD8+ T cells, thereby enhancing their role in tumor immunosurveillance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3501